The present disclosure relates to devices and systems for targeted and controlled delivery of a therapeutic agent to a treatment site of an eye. Particularly, aspects are directed to a therapeutic agent delivery device that includes a polymeric substrate having a release region, a delivery region, and a receiving region; one or more reservoirs formed within the release region; a therapeutic agent disposed within the one or more reservoirs; an active, passive, or combination thereof controlled release mechanism for release of the therapeutic agent from the one or more reservoirs into the delivery region; and a circuit formed on the polymeric substrate, the circuit having a current source, a first iontophoresis electrode located within the delivery region for transport of the therapeutic agent from the delivery region into a target tissue via electromigration, and a second iontophoresis electrode located within the receiving region for maintaining electroneutrality within the tissue.

Described herein are unit cells including a base plate; a top plate; and a lumen extending longitudinally from the base plate to the top plate, the lumen defined by a side wall formed from a plurality of cojoined panels extending between a bottom surface of the top plate and a top surface of the base plate. The unit cell can be magnetically actuatable, such that the unit cell can be reversibly transitioned between a contracted configuration, an extended configuration, or a combination thereof using an applied magnetic field.

Wireless and non-wireless drug delivery integrated circuits, systems, and methods of delivering therapeutic pharmaceutical compounds are provided. The system can include a control module, a wireless drug delivery integrated circuit, a first electrode and a second electrode that are both attached to the wireless drug delivery integrated circuit, an electroactive polymer, and a pharmaceutical compound. The electroactive polymer and the pharmaceutical compound can be formed as films on one of the electrodes and, when placed in a solution, a voltage potential can be applied across the electrodes causing the pharmaceutical compound to be released into the solution.

An implantable device contains a drug or biosensing compound, protected from the external environment within a human body by several barriers which are broken upon activation of the device through electrothermal, chemical, and mechanical processes. The device allows accurate and repeated dosing within a human body, thus reducing the number of implantation procedures required. This device extends the lifetime of a biosensor, reducing the number of implantation procedures required.

Ingestible event markers having high reliability are provided. Aspects of the ingestible event markers include a support, a control circuit, a first electrochemical material, a second electrochemical material and a membrane. In addition, the ingestible event markers may include one or more components that impart high reliability to the ingestible event marker. Further, the ingestible event markers may include an active agent. In some aspects, the active agent, such as a pharmaceutically active agent or a diagnostic agent may be associated with the membrane.

An implantable device contains a drug or biosensing compound, protected from the external environment within a human body by several barriers which are broken upon activation of the device through electrothermal, chemical, and mechanical processes. The device allows accurate and repeated dosing within a human body, thus reducing the number of implantation procedures required. This device extends the lifetime of a biosensor, reducing the number of implantation procedures required.

Technologies for managing a treatment program include a treatment management server, smart pills, and patient computing devices. The treatment management server is configured to generate treatment data usable by the smart pills to control a release of one or more drugs in patients. The treatment management server is also configured to transmit the treatment data to the smart pills, obtain physiological data associated with the patients, identify a preferred physiological response among the patients based on the physiological data, and identify the treatment data associated with the preferred physiological response. The smart pills are configured to obtain the treatment data, release one or more drugs into the patients based on the treatment data, sense physiological conditions in the patients, and transmit the physiological conditions to the treatment management server. The patient computing devices facilitate communication between the treatment management server and the smart pills. Other embodiments are described.

The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.

An implantable delivery device and method for utilizing the device to delivery a bioactive agent to a subject in need thereof is described. The device includes a pattern of structures fabricated on a surface of the device to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. The device may be located adjacent tissue such as an endovascular implant or a perivascular implant, and may deliver the bioactive agent without triggering an immune or foreign body response to the bioactive agent.

The invention provides compositions, kits and methods for depositing a composition comprising a plurality of magnetic particles, to a target site of a subject by delivering the composition via controlled inhalation to a region of the subject's respiratory tract and applying a magnetic field to a target site within the region of the subject's respiratory tract to capture the particles in said target site.